Fig. 7From: Active targeting of HER2-positive breast cancer cells by Herceptin-functionalized organically modified silica nanoparticlesThe amount of zeta potential for AOTORM nanoparticles with no dialysis (column 0Â day) and after 2, 4, 6, and 8Â days dialysis (a), and the amount of zeta potential for TWORM nanoparticles with no dialysis (column 0Â day) and after 2, 4, 6, and 8Â days dialysis (b)Back to article page